Plunkett Research Online: Hemostemix

HEMOSTEMIX (HEM:TSX) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Hemostemix Inc is a Canada based clinical-stage biotechnology company. Its principal business activity is to develop, manufacture and commercialize blood-derived cell therapies for medical conditions. The company’s technology platform for developing autologous cell therapies is for treatment of vasc.....



Hemostemix
Ticker: HEM
Exchange: TSX
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone:
Fax:
Address: 150 - 9th Avenue SW
Suite 1049
Calgary, AB T2P 3H9 Canada

Types Of Business
Industry Ranks

Industry NAICS code:

Holding Companies
ContactsDescription
Kyle MakofkaCEO/President
Kristin GulkaCFO
See More
Hemostemix Inc is a Canada based clinical-stage biotechnology company. Its principal business activity is to develop, manufacture and commercialize blood-derived cell therapies for medical conditions. The company’s technology platform for developing autologous cell therapies is for treatment of vasc.....See More See More

Auditor: Crowe MacKay LLP
Legal Advisor:
$USD, In whole numbers,
except marked * or %
201720162015201420142013
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: